BioCentury | Dec 9, 2020
Product Development

Dec. 8 Quick Takes: Amgen’s KRAS inhibitor nears FDA submission; plus Curis, BeiGene, Pfizer, Forma, Agios, Lyra, Bellicum, Illumina-Harvard Pilgrim

...in patients with previously treated metastatic pancreatic and prostate cancer.Illumina, Harvard Pilgrim partner on whole-genome sequencing Harvard Pilgrim Health Care Inc....
...R PSCA – Prostate stem cell antigen Sandi Wong Blincyto, blinatumomab (AMG 103, mt103, MEDI-538) sotorasib (AMG 510) Amgen Inc. BeiGene Ltd. Harvard Pilgrim Health Care Inc. Pfizer...
BioCentury | Nov 25, 2020
Regulation

With Oxlumo’s approval, Alnylam aims to speed access with new value-based pricing framework

...Holding Co. unit of Cigna Corp. (NYSE:CI), Harvard Pilgrim Health Care Inc....
BioCentury | Oct 31, 2020
Product Development

ICER’s influence on payers could translate to a seat at the table for government drug reviews

...It’s what ICER calls the ‘Grand Bargain,’” Harvard Pilgrim Health Care...
BioCentury | Oct 3, 2020
Product Development

Departing Alnylam, Greene has messages for industry from company building to product pricing

...outcomes-based payment model via an agreement with Harvard Pilgrim Health Care Inc....
BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

...to generate health economics data, could come from a risk-sharing arrangement piloted last year by Harvard Pilgrim Health Care...
BioCentury | Nov 21, 2019
Company News

Alnylam unveils pricing strategy for second FDA-approved RNAi drug

...with investors Wednesday. The company is discussing performance-based agreements with government and commercial payers including Harvard Pilgrim Health Care...
BioCentury | Sep 14, 2019
Company News

Sept. 9 Company Quick Takes: Alexion licenses Japanese rights to Eidos candidate; plus Molecular Partners-Allergan, Horizon, Alnylam

...by hereditary TTR-mediated amyloidosis (hATTR) in adults and simultaneously announced an outcomes-based payment model with Harvard Pilgrim Health Care Inc....
BioCentury | Aug 31, 2019
Product Development

Criteria of demarcation

...go into addressing disease states that can have similar digital solutions. Michael Sherman, CMO at Harvard Pilgrim Health Care Inc....
...Inc., Boston, Mass. Digital Therapeutics Alliance, Arlington, Va. European Medicines Agency (EMA), Amsterdam, the Netherlands Harvard Pilgrim Health Care Inc....
BioCentury | Aug 31, 2019
Product Development

Rethinking first principles

...to 18 weeks for Pear’s products and 14 weeks for Sleepio. Michael Sherman, CMO at Harvard Pilgrim Health Care Inc....
...Mateo, Calif. Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Harvard Medical School, Boston, Mass. Harvard Pilgrim Health Care Inc....
BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

...reimbursement for digital therapies (see “Digital Health: Payers Are Figuring Out What It’s Worth” ). Harvard Pilgrim Health Care Inc....
...NYSE:LLY), Indianapolis, Ind. Evidation Health Inc., San Mateo, Calif. Global Healthy Living Foundation, Nyak, N.Y. Harvard Pilgrim Health Care Inc....
Items per page:
1 - 10 of 96
BioCentury | Dec 9, 2020
Product Development

Dec. 8 Quick Takes: Amgen’s KRAS inhibitor nears FDA submission; plus Curis, BeiGene, Pfizer, Forma, Agios, Lyra, Bellicum, Illumina-Harvard Pilgrim

...in patients with previously treated metastatic pancreatic and prostate cancer.Illumina, Harvard Pilgrim partner on whole-genome sequencing Harvard Pilgrim Health Care Inc....
...R PSCA – Prostate stem cell antigen Sandi Wong Blincyto, blinatumomab (AMG 103, mt103, MEDI-538) sotorasib (AMG 510) Amgen Inc. BeiGene Ltd. Harvard Pilgrim Health Care Inc. Pfizer...
BioCentury | Nov 25, 2020
Regulation

With Oxlumo’s approval, Alnylam aims to speed access with new value-based pricing framework

...Holding Co. unit of Cigna Corp. (NYSE:CI), Harvard Pilgrim Health Care Inc....
BioCentury | Oct 31, 2020
Product Development

ICER’s influence on payers could translate to a seat at the table for government drug reviews

...It’s what ICER calls the ‘Grand Bargain,’” Harvard Pilgrim Health Care...
BioCentury | Oct 3, 2020
Product Development

Departing Alnylam, Greene has messages for industry from company building to product pricing

...outcomes-based payment model via an agreement with Harvard Pilgrim Health Care Inc....
BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

...to generate health economics data, could come from a risk-sharing arrangement piloted last year by Harvard Pilgrim Health Care...
BioCentury | Nov 21, 2019
Company News

Alnylam unveils pricing strategy for second FDA-approved RNAi drug

...with investors Wednesday. The company is discussing performance-based agreements with government and commercial payers including Harvard Pilgrim Health Care...
BioCentury | Sep 14, 2019
Company News

Sept. 9 Company Quick Takes: Alexion licenses Japanese rights to Eidos candidate; plus Molecular Partners-Allergan, Horizon, Alnylam

...by hereditary TTR-mediated amyloidosis (hATTR) in adults and simultaneously announced an outcomes-based payment model with Harvard Pilgrim Health Care Inc....
BioCentury | Aug 31, 2019
Product Development

Criteria of demarcation

...go into addressing disease states that can have similar digital solutions. Michael Sherman, CMO at Harvard Pilgrim Health Care Inc....
...Inc., Boston, Mass. Digital Therapeutics Alliance, Arlington, Va. European Medicines Agency (EMA), Amsterdam, the Netherlands Harvard Pilgrim Health Care Inc....
BioCentury | Aug 31, 2019
Product Development

Rethinking first principles

...to 18 weeks for Pear’s products and 14 weeks for Sleepio. Michael Sherman, CMO at Harvard Pilgrim Health Care Inc....
...Mateo, Calif. Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Harvard Medical School, Boston, Mass. Harvard Pilgrim Health Care Inc....
BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

...reimbursement for digital therapies (see “Digital Health: Payers Are Figuring Out What It’s Worth” ). Harvard Pilgrim Health Care Inc....
...NYSE:LLY), Indianapolis, Ind. Evidation Health Inc., San Mateo, Calif. Global Healthy Living Foundation, Nyak, N.Y. Harvard Pilgrim Health Care Inc....
Items per page:
1 - 10 of 96